Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jan;33(1):107-108.
doi: 10.1016/j.annonc.2021.09.009. Epub 2021 Sep 20.

Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study

F Nelli  1 , A Fabbri  2 , A Onorato  2 , D Giannarelli  3 , M A Silvestri  4 , J R Giron Berrios  2 , A Virtuoso  2 , E Marrucci  2 , C Signorelli  2 , M G Chilelli  2 , F Primi  2 , M Schirripa  2 , M Mazzotta  2 , E M Ruggeri  2
Affiliations
Observational Study

Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study

F Nelli et al. Ann Oncol. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclorure The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Antibody and seroconversion responses after either dose of mRNA-BNT162b2 vaccine. (A) Comparison of distributions and medians of anti-SARS-CoV-2 spike protein IgG titers (logarithmic values). Bars represent median values with 95% confidence interval. (B) Comparison of seroconversion response rates at a cut-off of 50 AU/ml. Control cohort, patients with discontinuation of active treatment by at least 28 days; exposed cohort, patients on active treatment within previous 28 days; timepoint-1, assessment before second mRNA-BNT162b2 vaccine dose; timepoint-3, assessment at 8 weeks after second vaccine dose.
See this image and copyright information in PMC

References

    1. Kong X., Qi Y., Huang J., et al. Epidemiological and clinical characteristics of cancer patients with COVID-19: a systematic review and meta-analysis of global data. Cancer Lett. 2021;508:30–46. - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
    1. Goshen-Lago T., Waldhorn I., Holland R., et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021 doi: 10.1001/jamaoncol.2021.2675. - DOI - PMC - PubMed
    1. Palich R., Veyri M., Marot S., et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol. 2021;32:1051–1053. - PMC - PubMed